Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data.
about
Biomarker-Based Approaches for Assessing Alcohol Use DisordersEpidemiology of fatty liver: an updateWhat should we recommend to our patients with NAFLD regarding alcohol use?The Potential of Non-Provitamin A Carotenoids for the Prevention and Treatment of Non-Alcoholic Fatty Liver DiseaseOxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosisTrajectories of Metabolic Risk Factors and Biochemical Markers prior to the Onset of Cardiovascular Disease - The Doetinchem Cohort StudyThe associations between serum biomarkers and stenosis of the coronary arteriesDyslipidemia in rural areas of North China: prevalence, characteristics, and predictive valueNon-alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do.The association of nonalcoholic fatty liver disease with central and peripheral blood pressure in adolescence: findings from a cross-sectional study.Non-alcoholic fatty liver disease.Compared with Powdered Lutein, a Lutein Nanoemulsion Increases Plasma and Liver Lutein, Protects against Hepatic Steatosis, and Affects Lipoprotein Metabolism in Guinea Pigs.MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice.Link Between Non-Alcoholic Fatty Liver Disease and Atrial Fibrillation: A Systematic Review and Meta-Analysis.Nonalcoholic fatty liver disease associated with impairment of kidney function in nondiabetes population.Offspring of mothers fed a high fat diet display hepatic cell cycle inhibition and associated changes in gene expression and DNA methylation.Computed tomography-derived cardiovascular risk markers, incident cardiovascular events, and all-cause mortality in nondiabetics: the Multi-Ethnic Study of AtherosclerosisImpacts of common factors of life style on serum liver enzymes.Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes?Liver function tests and risk prediction of incident type 2 diabetes: evaluation in two independent cohorts.Independent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis.Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Liver function parameters in hip fracture patients: relations to age, adipokines, comorbidities and outcomes.The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease.Diagnosis and evaluation of nonalcoholic fatty liver disease.Longitudinal Blood Pressure Control, Long-Term Mortality, and Predictive Utility of Serum Liver Enzymes and Bilirubin in Hypertensive Patients.Association of PNPLA3 rs738409 and TM6SF2 rs58542926 with health services utilization in a population-based study.The Framingham risk score and heart disease in nonalcoholic fatty liver disease.Alanine and aspartate aminotransferase and glutamine-cycling pathway: their roles in pathogenesis of metabolic syndrome.AAV vectors containing rDNA homology display increased chromosomal integration and transgene persistence.Focus on therapeutic strategies of nonalcoholic Fatty liver diseaseMultidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease.Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart diseasePlasma gamma-glutamyltransferase is strongly determined by acylation stimulating protein levels independent of insulin resistance in patients with acute coronary syndrome.The Effect of Roux-en-Y vs. Omega-Loop Gastric Bypass on Liver, Metabolic Parameters, and Weight Loss.Hepatic function and the cardiometabolic syndrome.Liver Enzymes and Risk of Ischemic Heart Disease and Type 2 Diabetes Mellitus: A Mendelian Randomization Study.Serum γ-glutamyltranspeptidase predicts all-cause, cardiovascular and liver mortality in older adults.Beyond Body Mass Index: Advantages of Abdominal Measurements for Recognizing Cardiometabolic Disorders.Fatty liver predicts the risk for cardiovascular events in middle-aged population: a population-based cohort study.
P2860
Q26772931-27D4BA32-0618-40E1-8DD6-5B49A82EEC59Q27000114-070344DD-1E5F-442F-863A-C2D7F207CE79Q27011312-C0BB187A-3F59-4849-818A-DB3F1ABD2D7BQ28070139-41E1B9F6-51E8-4703-B438-237A0C32BE56Q28084150-8E79D6C6-2404-442B-8E43-8A6F61E47309Q28394785-69A55F37-03DC-4183-A63E-479A5FC18C08Q28554584-A3FB727C-CFDA-4CF2-BBF7-B7D1415A9569Q28595874-866DD356-A640-40CE-A137-DF942D8FEA3CQ30401022-C3169C41-D950-40F1-A9E6-55DB7E1AD61DQ30418630-96EE419D-9160-4079-BDB4-DF97E8997D8CQ30430392-05C82684-832B-4D4C-ABD2-2FADAD2DB2EDQ31125932-E216E4AB-BC9A-4927-AAB6-A343D56FA7C0Q31132757-23AD938D-5BB9-4177-AD8D-7BCD23AD6A63Q33643887-5E923E94-976D-46E4-8D22-3B352BE56FC8Q33773127-B3C4269E-C347-4E62-B13A-4EB1C10FA36AQ33968085-736A81AF-7490-4104-9288-F2BDC7EE9992Q34115861-9F984157-837E-439A-BC4E-A87AE8B9D849Q34137334-B3B3DCEB-5284-48F3-A1C0-FCB21D141AD8Q34462325-20B7121F-85D2-4545-9413-49637DB75E01Q34531926-BD2E79B7-EBA4-4769-8269-A1BFDB436AE3Q34729697-9EE9642C-7A0B-468A-AAF7-998C11FE9DD2Q34830398-CFEB85A6-9D4B-4ABF-B772-D47964CCCD35Q34942815-D02C2C96-7479-450F-A84B-116302DC75FDQ35216649-14DF9991-EFC6-4F21-868A-11CF83CAE66EQ35495753-8649AE18-2409-4316-AA0B-5D4AA7D659C3Q35705464-BAA43A04-2D93-4C31-A8FD-1842789EF011Q35914994-287FE912-F6BB-4583-A10B-D7CC1D91C453Q35946523-1247C527-E054-49C1-AE96-F27D992AF1BAQ36144444-439E78B6-D145-4823-A8E2-605B125ECD1DQ36298638-3A4CE666-A373-4006-82AA-79A2BF3520F5Q36413703-19D1EF9B-03D9-4307-932F-6C52815A1B2FQ36470320-147A1516-4881-4E34-817E-DA6F231D5389Q37002532-5110D77B-9A3D-4FF7-B126-4FD08BA30862Q37176656-E65088F3-72D5-437B-9ABB-6047AC58E2ABQ37176686-36FF1D93-E24C-4015-BC1B-CC1E1E4BE34BQ37232122-5F14CAF4-A7C7-4C9D-ADBE-01260423340FQ37519086-8F6A71A7-1B5C-4419-9DA3-3FF16F363823Q37613314-F95BA4DA-44CD-45AB-8942-F87FBD2289A9Q37626016-59A409EA-01AE-4A8A-BC27-B4056B2D6C80Q37657417-630DE118-7FB2-45A9-B1A5-0A364C76096D
P2860
Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data.
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Liver enzymes, nonalcoholic fa ...... rspective of prospective data.
@ast
Liver enzymes, nonalcoholic fa ...... rspective of prospective data.
@en
type
label
Liver enzymes, nonalcoholic fa ...... rspective of prospective data.
@ast
Liver enzymes, nonalcoholic fa ...... rspective of prospective data.
@en
prefLabel
Liver enzymes, nonalcoholic fa ...... rspective of prospective data.
@ast
Liver enzymes, nonalcoholic fa ...... rspective of prospective data.
@en
P2860
P356
P1433
P1476
Liver enzymes, nonalcoholic fa ...... rspective of prospective data.
@en
P2093
Nazim Ghouri
P2860
P304
P356
10.1002/HEP.23789
P407
P577
2010-09-01T00:00:00Z